Related Experiment Video
Updated: Oct 1, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
Comparison of (123)I and (131)I for whole-body imaging in thyroid cancer
Salil D Sarkar1, Tomy P Kalapparambath, Christopher J Palestro
1Division of Nuclear Medicine, Department of Radiology, Long Island Jewish Medical Center, New Hyde Park, New York, USA. salil.sarkar@gte.net
Unlabelled:
We compared the diagnostic sensitivities of (123)I and (131)I whole-body imaging in differentiated thyroid cancer.
Methods:
Twelve thyroidectomized patients (3 previously treated with (131)I) were studied. After a period of thyroid hormone withdrawal, whole-body imaging was performed approximately 24 and 72-96 h after administration of 74-185 MBq (2-5 mCi) (123)I and 111-185 MBq (3-5 mCi) (131)I, respectively.
Results:
Both (123)I and (131)I revealed residual thyroid tissue, present in 9 patients. (131)I detected metastases in 5 studies of 4 patients. In 4 of 5 studies, (123)I missed metastases shown by (131)I in 8 body regions including the neck, mediastinum, lungs, and bone and detected 3 other sites of metastasis only in retrospect. No lesion was better seen with (123)I than with (131)I.
Conclusion:
Although (123)I is adequate for imaging residual thyroid tissue, it appears to be less sensitive than (131)I for imaging thyroid cancer metastases.
More Related Videos
Related Concept Videos
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Imaging Studies III: Computed Tomography
Radiological Investigation I: X-ray and CT
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

